COVID-19 Vaccine Grants

As a leader in the development of vaccines, Pfizer is proud to support independent efforts in areas of research, education and quality improvement with a primary goal of optimizing the prevention of COVID-19 . Given the urgency and complexity of efforts required to respond to the global pandemic, we are launching our COVID-19 vaccine grant program in phases.

As needs and gaps become clearer, we will be adding goals and areas of interest to the categories below. Please note the following:

Currently, we are not accepting applications for clinical research that studies the safety, immunogenicity, and/or efficacy of Pfizer’s COVID-19 vaccine.
To ensure vaccine availability for the general public, Pfizer is unable to provide COVID-19 vaccine as part of a grant.

COVID-19 VACCINE GENERAL RESEARCH

Learn more about General Research grants

The following areas of research will be considered:

Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.
Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer’s vaccine particularly in specific patient populations.
Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.

Submit a new application or view an existing application through our Grant System

COVID-19 VACCINE INDEPENDENT MEDICAL EDUCATION

Coming soon!

Optimize the prevention of COVID-19 by:

Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer’s vaccine.

COVID-19 VACCINE POPULATION HEALTH

Optimize the prevention of COVID-19 by increasing the understanding and familiarity with COVID-19 and Pfizer’s COVID-19 vaccine among the general population.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at www.cvdvaccine.com.

Learn to Vaccinate: Updated COVID-19 Clinician Resources

Clinicians will find a searchable database of accredited CE activities and links to key articles and other relevant, timely materials about COVID-19 and COVID-19 vaccines on this collaborative webpage from the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC).